Announcements
- Medigene to Present at ESMO Congress 2024
- Medigene AG Expands Patent Portfolio with the Patent Grant for its NY-ESO-1/LAGE 1a Targeted T Cell Receptor in China
- Medigene Presents Efficient 6-Day TCR-T Therapy Production Process with High Stemness
- Medigene Reports Results of Annual General Meeting
- Medigene to Present at the Cell and Gene Therapy In-Depth Focus Summit 2024
- Medigene AG Announces Lead Selection for MDG2021, Expanding TCR-T KRAS Library Targeting Solid Tumors
- Medigene AG Expands its End-to-End Platform by Submitting Three Development Optimization Technology Patents to the European Patent Office
- Medigene's Global Research & Collaboration Agreement with BioNTech to Extend Beyond Initially Announced Term
- Medigene Presents Preclinical Data on Optimal Affinity TCRs Targeting the Neoantigen Mutant KRAS
- Medigene AG Extends Cash Runway into July 2025 After Successful Oversubscribed Capital Raise
More ▼
Key statistics
On Monday, Medigene AG (MDG1k:DEU) closed at 1.12, 5.69% above its 52-week low of 1.06, set on Jul 01, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 1.16 |
---|---|
High | 1.19 |
Low | 1.10 |
Bid | 1.10 |
Offer | 1.17 |
Previous close | 1.14 |
Average volume | 21.45k |
---|---|
Shares outstanding | 29.48m |
Free float | 28.61m |
P/E (TTM) | -- |
Market cap | 33.75m EUR |
EPS (TTM) | -- |
Data delayed at least 15 minutes, as of Jul 29 2024.
More ▼